Clinical Trial News and Research

RSS

Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms

In a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside supplementation increased blood NAD levels but failed to improve clinical outcomes compared with placebo. Participants receiving the supplement had modestly worse overall disease scores, although the difference was below the threshold generally considered clinically meaningful.

12 Oct 2026

Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

Amphista Therapeutics Limited ('Amphista'), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase 1 trial for its lead candidate, AMX-883. Initiated following authorization from the U.S. Food and Drug Administration in June 2026, the BRAMLIE trial will investigate the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk MDS.

From Amphista Therapeutics 12 Oct 2026

A study links a blood protein to memory and brain changes in Down syndrome

Researchers studying 88 adults with Down syndrome and 43 controls estimated that serum β-synuclein increased approximately two decades before expected Alzheimer’s symptoms, preceding changes in other blood biomarkers. Higher levels correlated with poorer memory and brain changes, but the cross-sectional study could not distinguish whether the earliest increase reflected Alzheimer’s-related synaptic dysfunction, trisomy 21-related neurobiology, or both.

11 Oct 2026

A trial of 3,220 smokers puts cash rewards for quitting to the test

In a randomized trial of 3,220 medically underserved adults referred for lung cancer screening, adding financial incentives to usual care and free medication increased sustained smoking abstinence at six months. Offering free medication alone did not significantly increase quit rates, and adding a forward-looking mobile tool did not improve outcomes beyond the incentives.

11 Oct 2026

Therapeutic horseback riding reduces hyperactivity in children with autism

New research from the University of Colorado Anschutz provides strong evidence to suggest that horseback riding can help reduce hyperactivity and improve other behavioral and emotional challenges in children with autism and other psychiatric disorders.

9 Oct 2026

Cutting sugary drinks helps reduce childhood obesity, study finds

While the adult obesity rate appears to be slowing in the United States, childhood obesity remains historically high, affecting nearly 1 in 5 school-aged children.

9 Oct 2026

Sutter Health care model safely expands local Alzheimer's treatment

A multidisciplinary care model developed across Sutter Health helped general neurologists address a practical challenge facing health systems nationwide: how to safely offer newer Alzheimer's disease treatments in community settings to more patients.

9 Oct 2026

FDA approves atezolizumab combination for stage III colon cancer with deficient DNA mismatch repair

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

9 Oct 2026

Nicotinamide riboside fails to slow progression of early Parkinson’s disease

A major clinical trial involving 410 people with early Parkinson's disease has found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.

8 Oct 2026

Combination therapy overcomes immunotherapy resistance in glioblastoma

Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.

8 Oct 2026

Optogenetic therapy improves light sensitivity in people with retinitis pigmentosa

An international research team has reported new results from the first clinical cohort of blind people treated with an optogenetic therapy for advanced retinitis pigmentosa.

7 Oct 2026

Single tRNA controls prostate cancer identity and treatment resistance

Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease.

7 Oct 2026

Nerve-stimulation device enters human trials for cancer-related cachexia

The Terasaki Institute for Biomedical Innovation announced today that OnVagus, a medical device company incubating at the Institute, has received institutional and regulatory approval to begin the first human trial of its noninvasive nerve-stimulation device for patients experiencing cancer-related wasting.

7 Oct 2026

New modeling reveals high societal value of early Alzheimer's care

New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.

7 Oct 2026

NIH grant funds trial of wellness intervention for TBI caregivers

A University of Cincinnati College of Medicine physician-researcher has received a five-year, $2.5 million R01 grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health (NIH), marking a major career milestone.

6 Oct 2026

USC researchers receive $4 million to test psychedelic therapy and mindfulness for depression

A team of USC researchers has received an up to $4 million award from the Advanced Research Projects Agency for Health (ARPA-H) to conduct a clinical trial of psychedelic therapy and mindfulness training for depression.

6 Oct 2026

New AI model detects heart transplant rejection without biopsies

By analyzing heart rhythm recordings and blood tests, artificial intelligence may accurately flag when a transplant patient's body starts attacking a donated heart, a new study suggests.

6 Oct 2026

Mount Sinai adopts automated data integration for oncology clinical trials

The Mount Sinai Tisch Cancer Center has transitioned its electronic health record (EHR)-to-clinical trial data integration technology from pilot to routine use across its cancer research program.

6 Oct 2026

Enlicitide offers oral treatment option for patients avoiding cholesterol injections

In 2015, a new class of cholesterol-lowering injectable drugs called PCSK9-inhibitors was approved by the Food and Drug Administration (FDA) as a result of clinical research led by UT Southwestern.

5 Oct 2026

Osteopathic treatment safely improves head shape in infants with plagiocephaly

Physicians used osteopathic manipulative treatment to effectively improve the head shape of babies who developed a flattened spot on the back or side of their head, a condition called positional plagiocephaly (PP), according to research presented during the American Academy of Pediatrics 2026 National Conference & Exhibition in San Diego Oct. 2-6.

5 Oct 2026